Insmed Incorporated (IM8N STU) stock market data APIs
€168.3925
0(0%)
as of December 17, 2025
Try our APIs with
free plan!
Insmed Incorporated Financial Data Overview
Price chart is built with
Anychart
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Prev. Close
168.3925
Open
168.3925
High
168.3925
Low
168.3925
52 wk Range
55-184
Market Cap
36 043 M
Shares Outstanding
213 M
Revenue
447 M
EPS
-1.21
Beta
1.017
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Insmed Incorporated data using free add-ons & libraries
Get Insmed Incorporated Fundamental Data
Insmed Incorporated Fundamental data includes:
- Net Revenue: 447 M
- EBITDA: -978 790 016
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-02-23
- EPS/Forecast: -1.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Insmed Incorporated News
New
Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025
BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Is Insmed Incorporated (INSM) the Best Long Term Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands agains...
Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025
We recently published a list of 20 Stocks Insiders Were Selling In Q1 2025. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other stocks inside...
Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts
We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Insmed Incorporated (NASDAQ:INSM) stands against o...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
